摘要
目的：对人胰腺癌中转化生长因子β1（TGF－β1）及其血型受体（TβRⅡ）的表达进行研究，探讨其与胰腺癌进展、转移的关系。方法：应用SABC免疫组化方法检测TGF－βl、TβR－Ⅱ在10例正常胰腺，13例慢性胰腺炎和36例胰腺癌中的表达。结果：1．TGF－β1、TβⅡ阳性率在正常胰腺均为10．0％，慢性胰腺炎中分别为7．7％、15．4％，胰腺癌中分别为44．4％、47．2％，胰腺癌中的阳性率明显高于前两组（P＜0．05））；2．TGF－β1、TβRⅡ的表达与胰腺癌患者的年龄、性别、肿瘤的大小、位置、组织学分级无关（P＞005），与临床分期相关（P＜0．001）；3．TGF－β1、TβRⅡ在胰腺癌中共同阳性率为36．1％，其共同表达与胰腺癌的组织学分级和临床分期有关（P＜0．001）。结论：单独检测TGF－βl、TβRⅡ的表达对判断胰腺癌的进展、转移趋势有参考价值；二者共同表达对判断胰腺癌的恶性程度及进展、转移趋势有参考价值。
to explore the relationship of both expression of TGF － FI and T6R 11 and Progression, metastases of Pancreatic cancer. Method: Using strepto－ advidinbiotin complex(SABC) method, TGF －－ β1 and T6R Ⅱ expression in 10huma with normal pancreas, 13 with chronic pancreatitis and 36 with pancreatic ductal adenocarcinoma was examined immunohistochemically. Results: 1 ) TGF －－ β1 Positive rate was ic. 0%, 7. 7% and 44. 4%, respectively and TβR Ⅱ Positiverate was 10. 0%, 15. 4% and 47. 2%, respectively in the normal pancreas, chronic pancreatitis and pancreatic cancer. ThetWo protein positive rate in pancreatic cancer was increased significantly compared with normal pancreas and chronic pancreatitis(P < 0. 05). 2) TGF －－ FI and TAR 11 expression was not related to the age, sex of the patients, and site, size andhistopathological grade of tumors(P > 0. 05), but related to clinical stage of tumor(P < 0. 001 ). 3 ) Comexpreaxion rate ofTGF －－β1 and TAR Ⅱ was 36. l% (13/36). The coexpression in pancreatic cancer was correlated to the histopathologicalgrade and clinical stage of tumors(P < 0. 001 ). Conclusion: It will be usful to detect the expression of TGF －－ FI and TβR Ⅱin the human pancreatic cancer, for assess the procession and metases of pancreatic cancer. Examining coexpreaaion ofIF －β1 and T6R Ⅱ in pancreatic cancer will be helpful to evaluate its malignant degree, progresion and metastases.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第2期208-210,228,共4页
Chinese Journal of Cancer
基金
美国中华医学基金
关键词
胰腺癌
TGF-Β1
TβRⅡ
基因表达
Pancreatic cancer
Transforming berth factor －β1 (TGF －β1 )
Type Ⅱ of transforming growth factor －βreceptor(TPR Ⅱ)
Immunohischemistry
